Quick Answer
Silexion Therapeutics Corp reported Operating Income of -$11.63 million for fiscal year 2025.
Silexion Therapeutics Corp Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$11.63M | +7.5% |
| 2024 | -$12.57M | -168.6% |
| 2023 | -$4.68M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.29M | +59.0% | -44.1% |
| June 30, 2025 | -$2.28M | -64.9% | +71.6% |
| September 30, 2024 | -$8.04M | -999.3% | -480.2% |
| June 30, 2024 | -$1.39M | +2.1% | -89.5% |
| September 30, 2023 | -$731.0K | — | +48.3% |
| June 30, 2023 | -$1.41M | — | — |
- Silexion Therapeutics Corp showed an increase of +7.5% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Silexion Therapeutics Corp’s operating income has declined by 148.5% (from -$4.68 million to -$11.63 million).
- The most recent figure is from Silexion Therapeutics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: